Cullinan Therapeutics (CGEM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors, Nadim Ahmed and Stephen Webster, for a three-year term ending in 2029.
Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve named executive officer compensation.
Board will consider any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Audit committee and external auditor matters
Proposal to ratify KPMG LLP as the independent auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cullinan Therapeutics
- Promising T-cell engager data and strong cash position drive pipeline progress into 2029.CGEM
Guggenheim Securities 2nd Annual Healthcare Innovation Conference9 Jul 2026 - Transformative autoimmune and oncology programs advance, with strong data and financial runway.CGEM
Morgan Stanley 22nd Annual Global Healthcare Conference8 Jul 2026 - Key clinical data for autoimmune and oncology programs expected in 2026, backed by strong cash reserves.CGEM
Morgan Stanley 23rd Annual Global Healthcare Conference8 Jul 2026 - Key 2025 catalysts include pivotal autoimmune and oncology data, with T cell engagers leading innovation.CGEM
TD Cowen 45th Annual Healthcare Conference8 Jul 2026 - T cell engagers show robust efficacy in SLE and RA, with expanded trials and milestones ahead.CGEM
Immunology Day 202611 Jun 2026 - Net loss of $49.7M in Q1 2026; strong cash position supports major clinical milestones ahead.CGEM
Q1 20267 May 2026 - Transformational data from T-cell engager programs in autoimmune and AML expected in 2024–2026.CGEM
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance focus.CGEM
Proxy filing28 Apr 2026 - Key T-cell engager programs advance toward pivotal milestones and data readouts in 2026.CGEM
Leerink Global Healthcare Conference 202610 Mar 2026